Cargando…
Hepatitis B core-related antigen: Are we near a treatment endpoint?
Different serological and virological markers in chronic hepatitis B patients guide staging of viral infection, and initiation and response to therapy. Due to the persistence of intrahepatic covalently closed circular DNA (cccDNA) in the hepatocyte nucleus, hepatitis B is not curable. Even after und...
Autor principal: | Gupta, Tarana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346455/ https://www.ncbi.nlm.nih.gov/pubmed/36158266 http://dx.doi.org/10.3748/wjg.v28.i27.3532 |
Ejemplares similares
-
COVID-19 and liver disease: Are we missing something?
por: Gupta, Tarana
Publicado: (2022) -
Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy
por: Gök Sargın, Zeynep
Publicado: (2023) -
Testing for hepatitis B virus core antigen and e antigen may confer additional safety of donors’ blood negative for heptitis B virus surface antigen
por: Al-Joudi, Fawwaz Shakir, et al.
Publicado: (2014) -
Clinical relevance of hepatitis B core total antibody in the detection of occult hepatitis B infection in patients with liver disease and blood donors
por: Bajpai, Vijeta, et al.
Publicado: (2021) -
Nonalcoholic steatohepatitis and hepatocellular carcinoma: Beyond the boundaries of the liver
por: Gupta, Tarana
Publicado: (2022)